Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Medtronic Inc's Viva Cardiac Resynchronization Therapy-Pacemaker Available in U.S; receives FDA approval


Monday, 25 Aug 2014 10:00am EDT 

Medtronic Inc:Says U.S. Food and Drug Administration (FDA) approval of newest cardiac resynchronization therapy-pacemaker, Viva CRT-P, for indicated patients with heart failure or atrioventricular (AV) block.Viva CRT-P includes Medtronic-exclusive AdaptivCRT algorithm, which preserves normal heart rhythms and automatically adjusts to patient's needs, creating a customized therapy for each patient.It is the only algorithm demonstrated to improve heart failure patients' response to therapy and reduce risk of atrial fibrillation, or AF.Recent data also show the AdaptivCRT algorithm reduced 30-day hospital readmissions for heart failure by 47 percent and AF-related healthcare utilizations by 55 percent - important benefits since heart failure is costly problem and represents a cause of 30-day hospital readmissions. 

Company Quote

78.42
1.04 +1.34%
4:00pm EDT